Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2012

Global Markets Direct, January 2012, Pages: 134

Diffuse Large B-Cell Lymphoma – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2012', provides an overview of the Diffuse Large B-Cell Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma. 'Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Diffuse Large B-Cell Lymphoma.
- A review of the Diffuse Large B-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diffuse Large B-Cell Lymphoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Diffuse Large B-Cell Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Diffuse Large B-Cell Lymphoma Therapeutic Products under Development, Key Players in Diffuse Large B-Cell Lymphoma Therapeutics, Diffuse Large B-Cell Lymphoma Pipeline Overview, Diffuse Large B-Cell Lymphoma Pipeline, Diffuse Large B-Cell Lymphoma Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diffuse Large B-Cell Lymphoma Overview
Therapeutics Development
An Overview of Pipeline Products for Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma Therapeutics under Development by Companies
Diffuse Large B-Cell Lymphoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Diffuse Large B-Cell Lymphoma Therapeutics – Products under Development by Companies
Diffuse Large B-Cell Lymphoma Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Diffuse Large B-Cell Lymphoma Therapeutics Development
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Seattle Genetics, Inc.
Takeda Pharmaceutical Company Limited
Millennium Pharmaceuticals, Inc.
Pfizer Inc.
Teva Pharmaceutical Industries Limited
Cell Therapeutics, Inc.
Genmab A/S
Celgene Corporation
Incyte Corporation
IMMUNOMEDICS, INC
Telik, Inc.
Pharmacyclics, Inc.
Chipscreen Biosciences Ltd
Memgen, LLC.
Ascenta Therapeutics, Inc.
CureTech Ltd.
Cylene Pharmaceuticals, Inc.
Probiomed S.A. de C.V.
PharmaTech International, Inc.
Diffuse Large B-Cell Lymphoma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
RG7159 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Enzastaurin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Epirubicin + Vincristine + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Revlimid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ofatumumab + DHAP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pixantrone + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin + R-CHOP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EPOCH + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Cyclophosphamide + Hydroxydaunorubicin Hydrochloride + Oncovin + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Cyclophosphamide + Hydroxydaunorubicin Hydrochloride + Oncovin + Prednisone + Darbepoetin Alpha - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bexxar + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Doxorubicin + Vincristine + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DHAP + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ICE + RITUXIMAB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Rituximab + G-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Vincristine + Prednisone + Epirubicin + Rituximab + G-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Rituximab + G-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Prednisone + Epirubicin + Vinblastine + Rituximab + G-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-CHOP14 + Darbepoetin Alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab-HDS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bleomycin Sulfate + Rituximab + CHOP Regimen + EPOCH Regimen + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Methotrexate + Mitoxantrone Hydrochloride + Prednisolone + Prednisone + Vincristine Sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine + Filgrastim + Carboplatin + Etoposide + Ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lenalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PBO-326 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bortezomib + Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diffuse Large B-Cell Lymphoma Therapeutics – Drug Profile Updates
Diffuse Large B-Cell Lymphoma Therapeutics – Discontinued Products
Diffuse Large B-Cell Lymphoma Therapeutics - Dormant Products
Diffuse Large B-Cell Lymphoma – Product Development Milestones
Featured News & Press Releases
Dec 11, 2011: Micromet's Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma
Aug 23, 2011: Seattle Genetics Initiates Phase II Clinical Trial Of ADCETRIS In CD30-Positive Non-Hodgkin Lymphoma
May 17, 2011: Teva And CureTech Announce Positive Data From Phase II Study Of CT-011
May 03, 2011: Cell Therapeutics To Re-submit Pixantrone NDA
Mar 21, 2011: Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial In Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Feb 04, 2011: Takeda Announces Publication Of Phase II Trial Results Of Velcade In Journal Of Clinical Oncology
Dec 07, 2010: Pharmacyclics Reports Updated Clinical Results From Phase IA Trial Of PCI-32765
Sep 30, 2010: Avila Initiates Phase I Clinical Study Of AVL-292 For Treatment Of B Cell Cancers And Autoimmune Diseases
Dec 07, 2009: Seattle Genetics Reports Data from SGN-40 (Dacetuzumab) Phase Ib Combination Clinical Trials
Oct 21, 2009: Millennium Initiates Phase II Trial For Diffuse Large B-Cell Lymphoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Diffuse Large B-Cell Lymphoma, H1 2012
Products under Development for Diffuse Large B-Cell Lymphoma – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
F. Hoffmann-La Roche Ltd., H1 2012
Amgen Inc., H1 2012
Sanofi-Aventis, H1 2012
AstraZeneca PLC, H1 2012
Eli Lilly and Company, H1 2012
GlaxoSmithKline plc, H1 2012
Seattle Genetics, Inc., H1 2012
Takeda Pharmaceutical Company Limited, H1 2012
Millennium Pharmaceuticals, Inc., H1 2012
Pfizer Inc., H1 2012
Teva Pharmaceutical Industries Limited, H1 2012
Cell Therapeutics, Inc., H1 2012
Genmab A/S, H1 2012
Celgene Corporation, H1 2012
Incyte Corporation, H1 2012
IMMUNOMEDICS, INC, H1 2012
Telik, Inc., H1 2012
Pharmacyclics, Inc., H1 2012
Chipscreen Biosciences Ltd, H1 2012
Memgen, LLC., H1 2012
Ascenta Therapeutics, Inc., H1 2012
CureTech Ltd., H1 2012
Cylene Pharmaceuticals, Inc., H1 2012
Probiomed S.A. de C.V., H1 2012
PharmaTech International, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Diffuse Large B-Cell Lymphoma Therapeutics – Drug Profile Updates
Diffuse Large B-Cell Lymphoma Therapeutics – Discontinued Products
Diffuse Large B-Cell Lymphoma Therapeutics – Dormant Products
Diffuse Large B-Cell Lymphoma Therapeutics – Dormant Products (Contd..1)

List of Figures
Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2012
Products under Development for Diffuse Large B-Cell Lymphoma – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Lymphoma - Pipeline Review, H2 2012
• Chronic Lymphoblastic Lymphoma - Pipeline Review, H2 2012
• Non-Hodgkin Lymphoma - Pipeline Review, H2 2012
• Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012
• Lupus Nephritis - Pipeline Review, H1 2013
• Natural Killer Cell Lymphomas – Pipeline Review, H1 2013
• Pruritus - Pipeline Review, H1 2013
• HIV / AIDS – Pipeline Review, H1 2013
• Pruritus - Pipeline Review, H1 2012
• Candidiasis - Pipeline Review, H1 2013